Back to the list
Congress: ECR25
Poster Number: C-20736
Type: Poster: EPOS Radiologist (scientific)
Authorblock: J. Li; Shanghai/CN
Disclosures:
Jing‐Lu Li: Nothing to disclose
Keywords: Urinary Tract / Bladder, MR, Radiation therapy / Oncology, Cancer
References
  1. Ferro M, Tătaru OS, Musi G, et al. Modified glasgow prognostic score as a predictor of recurrence in patients with high grade non-muscle invasive bladder cancer undergoing intravesical bacillus calmette–guerin immunotherapy. Diagnostics 2022; 12(3):586. https://doi.org/10.3390/diagnostics12030586
  2. Barone B, Finati M, Cinelli F, et al. Bladder cancer and risk factors: data from a multi-institutional long-term analysis on cardiovascular disease and cancer incidence. J Pers Med 2023; 13(3):512. https://doi.org/10.3390/jpm13030512
  3. Compérat E, Amin MB, Cathomas R, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. The Lancet 2022; 400(10364):1712–1721. https://doi.org/10.1016/S0140-6736(22)01188-6
  4. Lenis AT, Lec PM, Chamie K, Mshs M. Bladder cancer: a review. JAMA 2020; 324(19):1980. https://doi.org/10.1001/jama.2020.17598
  5. Kim DK, Kim JW, Ro JY, et al. Plasmacytoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of clinicopathological features and survival outcomes. J Urol 2020;204(2):215–223. doi:10.1097/JU.0000000000000794.
  6. Cheng L, Davison DD, Adams J, et al. Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol 2014;89(1):73–111. https://doi.org/10.1016/j.critrevonc.2013.08.008
  7. Lotan Y, Bagrodia A, Passoni N, et al. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. Eur Urol 2013; 64(3):465–471. https://doi.org/10.1016/j.eururo.2013.03.043
  8. Margulis V, Lotan Y, Karakiewicz PI, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. JNCI J Natl Cancer Inst 2009; 101(2):114–119. https://doi.org/10.1093/jnci/djn451
  9. Ziaran S, Harsanyi S, Bevizova K, et al. Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence. Eur J Histochem 2020; 64(2). https://doi.org/10.4081/ejh.2020.3098
  10. Nassar AH, Umeton R, Kim J, et al. Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites. Clin Cancer Res 2019;25(8):2458–2470. https://doi.org/10.1158/1078-0432.CCR-18-3147
  11. Schrier BPh, Vriesema JLJ, Witjes JA, Kiemeney LALM, Schalken JA. The predictive value of p53, p27Kip1, and α-catenin for progression in superficial bladder carcinoma. Eur Urol 2006; 50(1):76–82. https://doi.org/10.1016/j.eururo.2005.12.041
  12. Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol 2003;169(4):1219–1228. https://doi.org/10.1097/01.ju.0000056085.58221.80
  13. Wu X, Lv D, Cai C, et al. A TP53-associated immune prognostic signature for the prediction of overall survival and therapeutic responses in muscle-invasive bladder cancer. Front Immunol 2020;11:590618https://doi.org/10.3389/fimmu.2020.590618
  14. Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 2021; 79(1):82–104. https://doi.org/10.1016/j.eururo.2020.03.055
  15. Donin NM, Lenis AT, Holden S, et al. Immunotherapy for the treatment of urothelial carcinoma. J Urol 2017; 197(1):14–22. https://doi.org/10.1016/j.juro.2016.02.3005
  16. Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol 2017; 35(19):2117–2124. https://doi.org/10.1200/JCO.2016.71.6795
  17. Kamimura K, Nakajo M, Yoneyama T, et al. Amide proton transfer imaging of tumors: theory, clinical applications, pitfalls, and future directions. Jpn J Radiol 2019; 37(2):109–116.  https://doi.org/10.1007/s11604-018-0787-3
  18. Zhou J, Heo HY, Knutsson L, Van Zijl PCM, Jiang S. APT-weighted MRI: techniques, current neuro applications, and challenging issues: APTw MRI for neuro applications. J Magn Reson Imaging 2019;50(2):347–364. https://doi.org/10.1002/jmri.26645
  19. Wang HJ, Cai Q, Huang YP, et al. Amide proton transfer-weighted MRI in predicting histologic grade of bladder cancer. Radiology 2022;305(1):127–134. https://doi.org/10.1148/radiol.211804
  20. Law BKH, King AD, Ai QY, et al. Head and neck tumors: amide proton transfer MRI. Radiology 2018;288(3):782–790. https://doi.org/10.1148/radiol.2018171528
  21. Zhou J, Tryggestad E, Wen Z, et al. Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat Med 2011; 17(1):130–134. https://doi.org/10.1038/nm.2268
  22. Kong L, Wen Z, Cai Q, et al. Amide proton transfer-weighted MRI and diffusion-weighted imaging in bladder cancer: a complementary tool to the VI-RADS. Acad Radiol 2024; 31(2):564–571. https://doi.org/10.1016/j.acra.2023.09.005
  23. Chang L, Xu X, Wu G, Cheng L. Predicting preoperative pathologic grades of bladder cancer using intravoxel incoherent motion and amide proton transfer-weighted imaging. Acad Radiol 2024; 31(4):1438–1446. https://doi.org/10.1016/j.acra.2023.09.044
  24. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006; 12(24):7369–7373. https://doi.org/10.1158/1078-0432.CCR-06-1472
  25. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007; 177(2):481–487. https://doi.org/10.1016/j.juro.2006.09.038
  26. Nahm FS. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol 2022; 75(1):25–36. https://doi.org/10.4097/kja.21209
  27. Li L, Chen W, Yan Z, et al. Comparative analysis of amide proton transfer MRI and diffusion-weighted imaging in assessing p53 and Ki-67 expression of rectal adenocarcinoma. J Magn Reson Imaging 2020;52(5):1487–1496. https://doi.org/10.1002/jmri.27212
  28. Yu H, Wen X, Wu P, et al. Can amide proton transfer-weighted imaging differentiate tumor grade and predict Ki-67 proliferation status of meningioma? Eur Radiol 2019; 29(10):5298–5306. https://doi.org/10.1007/s00330-019-06115-w
  29. Togao O, Yoshiura T, Keupp J, et al. Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades. Neuro-Oncol 2014; 16(3):441–448. https://doi.org/10.1093/neuonc/not158
  30. Nishie A, Takayama Y, Asayama Y, et al. Amide proton transfer imaging can predict tumor grade in rectal cancer. Magn Reson Imaging 2018;51:96-103. https://doi.org/10.1016/j.mri.2018.04.017
  31. Ambs S, Merriam WG, Ogunfusika MO, et al. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 1998; 4(12):1371–1376. https://doi.org/10.1038/3957

  32. Liu Z, Yu X, Xu L, Li Y, Zeng C. Current insight into the regulation of PD-L1 in cancer. Exp Hematol Oncol 2022; 11(1):44. https://doi.org/10.1186/s40164-022-00297-8

  33. Hays E, Bonavida B. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resist Updat 2019; 43:10–28. https://doi.org/10.1016/j.drup.2019.04.001

  34. Yoshida S, Takahara T, Kwee TC, Waseda Y, Kobayashi S, Fujii Y. DWI as an Imaging Biomarker for Bladder Cancer. Am J Roentgenol 2017; 208(6):1218–1228. https://doi.org/10.2214/AJR.17.17798

  35. Zhang K, Dai Y, Liu Y, et al. Soft tissue sarcoma: IVIM and DKI parameters correlate with Ki-67 labeling index on direct comparison of MRI and histopathological slices. Eur Radiol 2022; 32(8):5659–5668. https://doi.org/10.1007/s00330-022-08646-1

  36. Falk Delgado A, Van Westen D, Nilsson M, et al. Diagnostic value of alternative techniques to gadolinium-based contrast agents in MR neuroimaging—a comprehensive overview. Insights Imaging 2019;10(1):84. https://doi.org/10.1186/s13244-019-0771-1

  37. Sakata A, Okada T, Yamamoto A, et al. Grading glial tumors with amide proton transfer MR imaging: different analytical approaches. J Neurooncol 2015; 122(2):339–348. https://doi.org/10.1007/s11060-014-1715-8
GALLERY